International Myositis Society - Special Newsletter March 2026

The new Myositis issue for 2026 is online!

Read it now and click HERE

1. Idiopathic inflammatory myopathies: one year in review 2025
   M. Diomedi, F. Fattorini, S. Aliberti, L.M. Bianchessi, A. Castellucci, J. Schmidt, L. Cavagna, L. Carli, S. Barsotti
2. Shared governance of international myositis networks
   T. Liewluck, L.G. Rider, K. Cheng, H. Chinoy, M.M. Dimachkie, E. Dourado, P.C. Gandiga, D.A. Isenberg, K. Ardalan, S. Keret, S. Kim, P. Korsten, I.E. Lundberg, P.M. Machado, F.W. Miller, C. Papadopoulou, S. Rosina, L.A. Saketkoo, S. Schlüter, J. Vencovský, A.J. Van Der Kooi, J. Schmidt
3. The MicroIBioM study: the gut microbiome in inclusion body myositis
   M. Winkler, W. Seel, C. Kornblum, M.-C. Simon, J. Reimann
4. Comparison of pre- and post-natal environmental exposures in United States versus Brazilian patients with juvenile dermatomyositis
   T.M. Arabi, S.C. Farhat, C.C. Valoes, S. Shenoi, S. Kim, B.O. Carneiro, L.G. Rider, A.M. Elias
5. Predictors of thrombotic events in patients with idiopathic inflammatory myopathies
   S.S. Bae, J. Wang, A. Shahbazian, D. Markovic, Y. Lee, T. De Leon, D. Elashoff, C. Charles-Schoeman
6. Analysis of clinical features and risk factors for patients with idiopathic inflammatory myopathy complicated by Pneumocystis jirovecii pneumonia
   J. Li, W. Huang, F. Ren, L. Luo, D. Chen, D. Huang, J. Zhou, L. Tang
7. Pneumocystis jirovecii pneumonia in anti-MDA5-positive dermatomyositis: characterisation, risk factors and prognosis
   L. Yang, Q. Yang, J. Li, L. Zhang, S. Liu, C. Lian
8. Cardiac involvement in patients with anti-melanoma differentiation-associated gene-5 antibody-positive dermatomyositis
   Y. Wang, X. Chen, Z. Huang, Y. Wang, W. Jiang, J. Lei, S. Xie, L. Zhang
9. Short Form 36 (SF-36) health survey questionnaire in health-related quality of life assessment in patients with inflammatory myopathies
   A. Razok, J. Taylor, E. Ritz, K. Wipfler, K. Michaud, D. Saygin
10. Prevalence and early detection of myocarditis in idiopathic inflammatory myopathies: a prospective single-centre study
    C.R. Calhoun, C.M. Connolly, J. Albayda, E. Tiniakou, C. Mecoli, B. Adler, L. Christopher-Stine, L. Adamo, S.L. Zimmerman, N.N. Gilotra, J. Paik
11. Clinical phenotypes and long-term outcomes of anti-SRP versus anti-HMGCR immune-mediated necrotising myopathy: a 13-year single-centre study
    K.E. Clark, L.M. Clayton, R.G. Thomas, S.G. Kelly, L. Walker, A.S. Herrey, A. Dougan, R.S. Patel, S. Fhadil, T.O. Millner, S. Marino, A. Radunovic
12. Peripheral blood immunophenotypic diversity in patients with anti-MDA5+ dermatomyositis and its impact on prognosis
    Y. Zhang, R. Liu, W. Hu, T. Li, T. Li, W. Guan, L. Zhang, Y. He, C. Lian, J. Sun, S. Liu, P. Zhang
13. Assessment of myositis specific antibodies in primary chronic arthritis: single centre prospective study
    G. Zanframundo, L.M. Bianchessi, V. Codullo, F. Bottazzi, M. Guerini, L. De Stefano, F. Niedda, C. Alpini, R. Caporali, S. Bugatti, C. Montecucco, L. Cavagna
14. Alterations of mucosal-associated invariant T cells in dermatomyositis
    S. Ye, J. Du, Y. Zhang, W. Wei, Y. Li
15. Health-related quality of life improvements and response thresholds of myositis outcome measures and response criteria
    M. Almackenzie, A. Aggarwal, S. Keret, T. Chandra, R. Lomanto Silva, E. Gkiaouraki, N. Pongtarakulpanit, S. Moghadam-Kia, C.V. Oddis, R. Aggarwal
16. The Refractory DermatoMyositis Index (ReDMI): a clinical tool to predict refractory disease in patients with dermatomyositis
    Y. Reyna-Juárez, N.R. Mejía-Domínguez, M.J. Ostos-Prado, B. Alcalá-Carmona, J.T. Balderas-Miranda, A. Gaytán, A. Hernández-López, C.A. Núñez-Álvarez, M.E. Baños-Laredo, M.L. Domínguez-López, K. Santana De Anda, D. Gómez-Martín, J. Torres-Ruiz
17. Janus kinase inhibitors therapy in idiopathic inflammatory myopathies: a case series
    A.L. Vasconcelos, A. Marinho, A. Campar
18. Potential pitfalls in the differential diagnosis of myositis versus hereditary myopathies
    S. Glaubitz, R. Zeng, K. Hasanov, S. Pauli, J. Schmidt
    
19. Factors associated with endomysial fibrosis in anti-signal recognition particle antibody immune-mediated necrotising myopathy
    J. Yuan, M. Yang, Y. Zheng, H. Hao, F. Gao, W. Zhang, Z. Wang, Y. Yuan, Y. Zhao
20. Cardiac involvement in newly diagnosed patients with idiopathic inflammatory myopathies is associated with skeletal muscle involvement
    B. Hanna, C.L. Polte, E. Sakiniene, J. Von Brömsen, E. Bollano, I.E. Lundberg, R. Pullerits, T. Jin
21. Validation of simplified scoring systems for assessing cutaneous disease activity in dermatomyositis
    N. Pongtarakulpanit, A. Bishnoi, T. Chandra, S. Dzanko, E. Gkiaouraki, S. Keret, R. Lomanto Silva, S. Sriram, D. Saygin, V.M. Liarski, D.P. Ascherman, S. Moghadam-Kia, C.V. Oddis, R. Aggarwal
    
22. Recurrent and new primary cancer risk in adult patients with idiopathic inflammatory myositis and a history of malignancy
    X. Wang, J. Albayda, J.J. Paik, E. Tiniakou, B.L. Adler, A.L. Mammen, L. Casciola-Rosen, L. Christopher-Stine, C.A. Mecoli
23. Fitbit as an activity monitor in idiopathic inflammatory myopathy: results from a real-world cohort
    A. Sharma, S. Keret, B. Rockette-Wagner, R. Lomanto Silva, T. Chandra, S. Moghadam-Kia, C.V. Oddis, R. Aggarwal
24. Non-inflammatory mimickers of myositis: a guide for rheumatologists
    S.P. Silva, M. Pinto, D. Costa, A. Azevedo, E. Dourado
25. Shaping the landscape of interstitial lung disease in idiopathic inflammatory myopathies: state of the art, evidence gaps and a need for clinical trials
    D. Rivero Gallegos, F.M. Pais, T. Lan, C. Papadopoulou, E.K. Joerns, J. Paul, J. Rojas Serrano, T. Kulkarni, P.C. Gandiga, H. So, K. Houghton, N. Bagri, M. Jansen, B. Bader Meunier, E.M. Wilfong, R. Aggarwal, R.W. Hallowell, V. Nagaraja
26. Pain in myositis: prevalence, assessment, potential mechanisms and considerations for management
    S. Glaubitz, Y.C. Lee, D. Saygin
27. Mitochondrial abnormalities in idiopathic inflammatory myopathies
    F. Torri, G. Ricci, M. Mancuso, G. Siciliano
28. Treatment outcomes in 63 cases of juvenile dermatomyositis-associated calcinosis
    B.Y. Yi, D.M. Wahezi, L. Covert, K. Ardalan, J. Hui-Yuen, N. Vasquez-Canizares, D.M. Mosa, M. Jones, C. Correll, A. Begezda, S. Shenoi, E.Y. Wu, L.K. Kovalick, W.B. Lapin, S.E. Tarvin, M.S. Oliver, M.M. Rodriguez, I. Marmor, K.W. Baszis, A.J. Taxter, A.C. Hanson, C.S. Crowson, A.B. Orandi
    for the CARRA Juvenile Dermatomyositis, Calcinosis Subcommittee
29. Association of NXP2 autoantibodies with a more severe clinical phenotype of juvenile dermatomyositis
    Y. Wang, J. Liang, J. Wang, F. Zheng, L. Teng, Q. Ma, Y. Zhou, L. Liang, J. Lin, M. Lu, H. Cao, X. Xu
30. Successful therapy of refractory dermatomyositis skin rash with anifrolumab
    C. Galluzzo, N. Pipitone, I. Chiapparoli, C. Salvarani.
31. Statins and ribociclib interaction induced necrotising myopathy: a case report and literature review
    F. Torri, G. Vadi, G. Aringhieri, G. Alì, F. Siciliano, G. Ricci, G. Siciliano
    
32. Comment on: Triple-combination therapy did not improve prognosis in anti-MDA5 positive dermatomyositis: a multicentre longitudinal cohort study by You et al.
    W. Rojas-Zuleta
33. Comment on: Successful management of pulmonary hypertension with baricitinib in a dermatomyositis patient
    C. Pinto Oliveira, M.D. Pascoal, A.R. Prata, D. Carvalho, M.G. Castro, E. Dourado
34. Reply to the comment on: Successful management of pulmonary hypertension with baricitinib in a dermatomyositis patient
    C. Rizzo, L. La Barbera, G. Guggino
35. Efficacy of rituximab treatment in a post-COVID-19 vaccine myositis overlapping to systemic sclerosis: a histological follow-up
    F. Bandinelli, G. Dallagiacoma, F. Nozzoli, M. Capassoni, R. Nassini
36. Neutrophil-to-lymphocyte ratio as a prognostic indicator in anti-MDA5 dermatomyositis with interstitial lung disease and its link to IFN-α and IL-6
    Y. Endo, T. Koga, Y. Mizunoo, T. Shimizu, N. Sakamoto, A. Kawakami
37. Comment on: Cancer-associated myositis before and after the COVID-19 pandemic onset
    F.M. Costa, R. Campanilho-Marques, E. Dourado, M. Bandeira, B. Correia, A.T. Melo, F. Saraiva, S.C. Barreira, J.E. Fonseca
38. Reply to the comment on: Cancer-associated myositis before and after the COVID-19 pandemic onset
    H. Daungsupawong, V. Wiwanitkit
39. Dermatomyositis assessment of rash via telemedicine: a preliminary study
    N. Pongtarakulpanit, A. Bishnoi, D.P. Ascherman, S. Moghadam-Kia, C.V. Oddis, R. Aggarwal
40. Complete clinical and serological remission of anti-synthetase syndrome after autologous haematopoietic stem cell transplantation
    V. Ruiz-Esquide, S. Prieto-Gonzalez, E. Ruiz-Ortiz, C. Arnaldos
41. Acquired generalised lipodystrophy as an uncommon complication of anti-Mi-2 dermatomyositis: a case report
    A. Bustos-Merlo, M. Martín-Armada, M. Zamora-Pasadas, I. Sánchez-Berná, N. Navarrete-Navarrete

Follow iMyoS on social media